di Reumatologia, Società Italiana, trans. 2026. “PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients With Active Axial Spondyloarthritis Treated With Bimekizumab: 52-Week Results from Two Phase 3 Studies: Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim Am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany”. Reumatismo 77 (s1). https://doi.org/10.4081/reumatismo.2025.2282.